4-ethyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl acetate

Catalog No. :
ACVMGS452
CAS No. :
7688-64-4
Molecular Formula :
C22H18N2O5
Molecular Weight :
390.39

IUPAC Name:4-ethyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl acetate

4-ethyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl acetate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
10mg95%$88.00Login to see priceInquiryInquiry
25mg95%$175.00Login to see priceInquiryInquiry
50mg95%$272.00Login to see priceInquiryInquiry
100mg95%$433.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-ethyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl acetate
IUPAC Name4-ethyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl acetate
Molecular FormulaC22H18N2O5
Molecular Weight390.39
SMILESCCC1(OC(C)=O)C(=O)OCC2=C1C=C1C3=C(C=C4C=CC=CC4=N3)CN1C2=O
InChI KeyASVIEXKOXDCZDF-UHFFFAOYSA-N
SynonymO-acetylcamptothecin;1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-(acetyloxy)-4-ethyl-, (4S)-;20-O-Acetylcamptothecin
CAS No.7688-64-4

Synthetic Route by SureRoute

1. ACVMGS452 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACVMGS452 route product structure diagram
    ACVMGS4527688-64-4
Inquiry

2. ACVMGS452 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACCZIU451 route compound structure diagram
    ACCZIU451563-67-7 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACVMGS452 route product structure diagram
    ACVMGS4527688-64-4
Inquiry

Comments (0)